Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Darcy

Showing results (161-170 of 222) with videos related to

Pageof 23
Sort By:
Gynecologic Oncology|June 12, 2012
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II studyDana M Chase, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|March 2, 2010
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterusWarner K Huh, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group StudyJean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
Military Medicine|April 16, 2025
Surgical Management of Endometrial Intraepithelial Neoplasia at Military Treatment Facilities: A Multicenter Retrospective StudyRebecca W Gregg, Ji Won Kim, Kathleen R Lundeberg, et al.
Genes, Chromosomes & Cancer|July 8, 2010
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcomeCarl Morrison, Jeffrey Miecznikowski, Kathleen M Darcy, et al.
Gynecologic Oncology Reports|September 14, 2019
Sixteen year-old with leiomyosarcoma in a prior benign myomectomy siteJennifer A Vaz, Payam Katebi Kashi, Saeid Movahedi-Lankarani, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
Gynecologic Oncology|April 23, 2013
Transcript expression in endometrial cancers from Black and White patientsG Larry Maxwell, Jay Allard, Chandramouli V R Gadisetti, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 13, 2017
Relative Effects of Age, Race, and Stage on Mortality in Gestational ChoriocarcinomaChristopher M Tarney, Chunqiao Tian, Eric R Craig, et al.
Gynecologic Oncology|January 20, 2020
Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilitiesJennifer Vaz, Chunqiao Tian, Michael T Richardson, et al.
Pageof 23

Showing results (161-170 of 222) with videos related to

Sort By:
Pageof 23
Gynecologic Oncology|June 12, 2012
Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II studyDana M Chase, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology|March 2, 2010
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterusWarner K Huh, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group StudyJean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
Military Medicine|April 16, 2025
Surgical Management of Endometrial Intraepithelial Neoplasia at Military Treatment Facilities: A Multicenter Retrospective StudyRebecca W Gregg, Ji Won Kim, Kathleen R Lundeberg, et al.
Genes, Chromosomes & Cancer|July 8, 2010
A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcomeCarl Morrison, Jeffrey Miecznikowski, Kathleen M Darcy, et al.
Gynecologic Oncology Reports|September 14, 2019
Sixteen year-old with leiomyosarcoma in a prior benign myomectomy siteJennifer A Vaz, Payam Katebi Kashi, Saeid Movahedi-Lankarani, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
Gynecologic Oncology|April 23, 2013
Transcript expression in endometrial cancers from Black and White patientsG Larry Maxwell, Jay Allard, Chandramouli V R Gadisetti, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 13, 2017
Relative Effects of Age, Race, and Stage on Mortality in Gestational ChoriocarcinomaChristopher M Tarney, Chunqiao Tian, Eric R Craig, et al.
Gynecologic Oncology|January 20, 2020
Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilitiesJennifer Vaz, Chunqiao Tian, Michael T Richardson, et al.
Pageof 23